ArticleThoracic cancer2022

Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.

Zihua Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.